• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

    5/8/25 4:15:38 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CDTX alert in real time by email
    • Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025
    • Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune status
    • Conference call and webcast today at 5:00 PM Eastern Time

    SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided recent business updates.

    "Coinciding with the end of the 2024-2025 flu season in the Northern Hemisphere, we have established April 30, 2025 as the data cutoff for the primary efficacy analysis of the 5,041 subjects dosed in the Phase 2b NAVIGATE clinical trial. We are expecting top-line results in late June of this year. The severity of the 2024-2025 flu season has provided an opportunity to discuss changes to the study's statistical analysis plan with the U.S. FDA to evaluate the potential statistical significance of CD388 versus placebo," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "We believe CD388 is highly differentiated from vaccines and monoclonal antibodies and we believe these differences can significantly improve upon the protective efficacy against influenza in healthy, high-risk, and immunocompromised patients with a single dose per flu season."

    Recent and Expected Corporate Highlights

    • Phase 2b NAVIGATE trial evaluating CD388 for prevention of seasonal influenza ongoing. Dosing of 5,041 subjects in the Phase 2b NAVIGATE study were completed in early December of 2024 across clinical sites in the U.S. and UK. This is a randomized, double-blind, controlled trial designed to evaluate the efficacy and safety of CD388 for the pre-exposure prophylaxis of seasonal influenza. Three CD388 dose groups, comprised of 150mg, 300mg and 450mg doses, and one placebo group were randomized and dosed in a 1:1:1:1 ratio at the beginning of the 2024-25 influenza season. Subjects were followed for efficacy through the end of April 2025 to monitor for breakthrough cases. Rates of laboratory and clinically confirmed influenza will be compared between subjects receiving the various single doses of CD388 or placebo.
    • Phase 2b NAVIGATE efficacy data expected in late June 2025. Due to the severity of the 2024-25 flu season, Cidara has the opportunity to discuss changes to the study's statistical analysis plan with the U.S. FDA, to evaluate possible statistical significance of CD388 versus placebo. Assuming agreement with the FDA on the changes to the statistical analysis plan, we expect that data from this trial will enable dose selection for Phase 3 as well as the determination of statistically meaningful comparisons of each dose to the placebo arm of the study.
    • Published preclinical data of CD388 in Nature Microbiology in March 2025. The article, entitled "Drug-FC Conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice," highlighted the potential of CD388 as a potent, universal antiviral for influenza A and B prevention regardless of immune status. The full press release can be found here.
    • Presented two posters on CD388 in influenza at the 38th International Conference on Antiviral Research (ICAR) in March 2025. The Company's presentations highlighted the study design, demographic information, and preliminary safety data from the ongoing Phase 2b NAVIGATE trial of CD388, as well as dose optimization models for its planned Phase 3 development program. The preliminary safety profile shows that CD388 is well-tolerated and the majority of injection site reactions are considered mild in severity.
    • Promoted Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Senior Vice President, Clinical Development. In May 2025, Cidara announced the promotions of Nicole Davarpanah, M.D., J.D., to Chief Medical Officer and Corrina Pavetto to Senior Vice President, Clinical Development. Dr. Davarpanah and Ms. Pavetto have shown exceptional leadership in the execution of the Phase 2b NAVIGATE Study, the revision of its statistical analysis plan, and the design of the Phase 3 development and regulatory strategy for CD388. Their continued guidance and oversight will be invaluable for the successful development of CD388 as a novel option for the universal prevention of influenza.

    First Quarter 2025 Financial Results

    • Cash, cash equivalents and restricted cash totaled $174.5 million as of March 31, 2025, compared with $196.2 million as of December 31, 2024.
    • Collaboration revenue was zero for the three months ended March 31, 2025, compared to $1.0 million for the same period in 2024. Collaboration revenue related to research and development (R&D) and clinical supply services provided to J&J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), under our license and collaboration agreement with Janssen (the Janssen Collaboration Agreement). The Janssen Collaboration Agreement was terminated upon the effectiveness of our license and technology transfer agreement with Janssen on April 24, 2024.
    • R&D expenses were $24.6 million for the three months ended March 31, 2025, compared to $5.9 million for the same period in 2024. The increase in R&D expenses is primarily driven by higher expenses associated with our ongoing CD388 Phase 2b NAVIGATE study and higher one-time personnel costs, partially offset by lower nonclinical expenses associated with our Cloudbreak platform.
    • General and administrative (G&A) expenses were $6.2 million for the three months ended March 31, 2025, compared to $3.6 million for the same period in 2024. The increase in G&A expenses is primarily due to higher personnel costs, partially offset by lower legal costs.
    • Net loss from discontinued operations for the three months ended March 31, 2025 was zero, compared to net loss from discontinued operations of $2.1 million for the same period in 2024. On April 24, 2024, Cidara entered into an asset purchase agreement with Napp Pharmaceutical Group Limited (Napp), an affiliate of Mundipharma Medical Company, pursuant to which all rezafungin assets and related contracts were sold to Napp. All conditions of the sale were completed on April 24, 2024, and the financial results of rezafungin have been reported separately as discontinued operations.
    • Net loss for the three months ended March 31, 2025 was $23.5 million, compared to a net loss of $10.3 million for the same period in 2024.

    First Quarter 2025 Conference Call and Webcast Details

    Cidara Therapeutics management will host a conference call and webcast beginning at 5:00 pm ET / 2:00 pm PT today, May 8, 2025. A live webcast may be accessed here. The conference call can be accessed by dialing toll-free (800) 717-1738 or (646) 307-1865 (international). The passcode for the conference call is 90743.

    A replay of the webcast will be archived on www.cidara.com for one year under the "Events & Presentations" tab in the Investors section of the company's website.

    About Cidara Therapeutics

    Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "anticipates," "expect," "intends," "believes," "may," "plan" or "will". Forward-looking statements in this release include, but are not limited to, statements related to the potential benefits of and future plans for CD388, the expected timing for reporting top-line data from the Phase 2b NAVIGATE clinical trial, the potential impact of discussions with the FDA and data from the Phase 2b NAVIGATE clinical trial and a potential Phase 3 study. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara's clinical trials and other risks related to clinical development, delays in action by regulatory authorities and other risks and uncertainties associated with Cidara's business in general. These and other risks are identified under the caption "Risk Factors" in Cidara's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and other filings subsequently made with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    [email protected]

    MEDIA CONTACT:

    Michael Fitzhugh

    LifeSci Communications

    [email protected]

     
    CIDARA THERAPEUTICS, INC.



    Condensed Consolidated Statements of Operations (unaudited)
     
     Three Months Ended

    March 31,
    (In thousands, except share and per share data) 2025   2024 
    Revenues:   
    Collaboration revenue$—  $973 
    Total revenues —   973 
    Operating expenses:   
    Research and development 24,600   5,919 
    General and administrative 6,179   3,596 
    Reversal of indirect tax liabilities (5,510)  — 
    Total operating expenses 25,269   9,515 
    Loss from operations (25,269)  (8,542)
    Other income (expense), net:   
    Other expense, net (110)  — 
    Interest income, net 1,899   365 
    Total other income, net 1,789   365 
    Net loss from continuing operations (23,480)  (8,177)
    Loss from discontinued operations, net of income taxes —   (2,149)
    Net loss and comprehensive loss$(23,480) $(10,326)
        
    Basic and diluted net loss per common share from continuing operations$(1.66) $(1.80)
    Basic and diluted net loss per common share from discontinued operations —   (0.48)
    Basic and diluted net loss per common share$(1.66) $(2.28)
        
    Shares used to compute basic and diluted net loss per common share 14,177,743   4,537,782 
            



    Condensed Consolidated Balance Sheet Data
     
     March 31, 2025 December 31, 2024
    (In thousands)(unaudited)  
    Cash, cash equivalents and restricted cash$174,489  $196,177 
    Total assets 191,727   214,796 
    Total liabilities 50,045   51,488 
    Total stockholders' equity 141,682   163,308 
            


    Primary Logo

    Get the next $CDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDTX

    DatePrice TargetRatingAnalyst
    3/12/2025$46.00Mkt Outperform
    Citizens JMP
    1/27/2025Overweight
    Cantor Fitzgerald
    12/13/2024$34.00Outperform
    RBC Capital Mkts
    11/8/2024$33.00Buy
    Guggenheim
    8/14/2024$24.00Neutral → Buy
    H.C. Wainwright
    12/3/2021$6.00Buy
    H.C. Wainwright
    9/22/2021$9.00 → $8.00Buy
    Aegis Capital
    9/22/2021$6.25Buy → Strong Buy
    WBB Securities
    More analyst ratings

    $CDTX
    SEC Filings

    See more
    • SEC Form S-3 filed by Cidara Therapeutics Inc.

      S-3 - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 5:25:12 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cidara Therapeutics Inc.

      10-Q - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 4:47:25 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/8/25 4:25:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Stein Jeffrey bought $105,680 worth of shares (8,000 units at $13.21) (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      6/11/24 6:26:28 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025. "These promotions come at a pivotal time as we continue advancing our influenza antiviral candidate, CD388, through our Phase 2b NAVIGATE trial and plan for Phase 3," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "Nicole and Corrina have shown exceptional

      5/1/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Participate in The Citizens Life Sciences Conference

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. The replay of the presentation will be available for at least 30 days. Cidara will also

      4/30/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Cidara Therapeutics with a new price target

      Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00

      3/12/25 7:22:04 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Cidara Therapeutics

      Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight

      1/27/25 8:36:28 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Cidara Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00

      12/13/24 7:27:23 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/9/24 5:37:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/4/24 4:15:14 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/3/24 4:34:49 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Financials

    Live finance-specific insights

    See more

    $CDTX
    Leadership Updates

    Live Leadership Updates

    See more

    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, May 8, 2025Time:5:00 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferen

      4/24/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

      - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve

      4/24/24 4:05:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program

      3/6/25 4:35:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

      SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e

      2/18/25 4:15:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Stein Jeffrey

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      4/2/25 6:28:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO & CLO Ward Shane was granted 25,000 shares, increasing direct ownership by 170% to 39,674 units (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      4/2/25 6:27:34 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COO & CLO Ward Shane sold $36,542 worth of shares (1,664 units at $21.96), decreasing direct ownership by 10% to 14,674 units (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      3/13/25 6:34:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care